February 3, 2017
Full Meeting Report
By: Richard Wolitski, Ph.D., Director, Office of HIV/AIDS and Infectious Disease Policy, U.S. Department of Health and Human Services and Corinna Dan, R.N., M.P.H., Viral Hepatitis Policy Advisor, Office of HIV/AIDS and Infectious Disease Policy, U.S. Department of Health and Human Services
In September 2016 HHS hosted a multi-stakeholder meeting, Expert Consultation on the Evidence for Early Hepatitis C Treatment in the United States to identify barriers to accessing hepatitis C treatment and potential strategies for ensuring that people who are infected can get the recommended treatment. This meeting focused specifically on the perspectives, data, and experiences that inform health care policies and practices. It did not tackle the issues, perspectives, and experiences of the pharmaceutical industry. A total of 34 healthcare experts participated including payers, academic researchers, hepatitis advocates, and federal partners.
While several treatments that cure over 90% of individuals with hepatitis C virus (HCV) are now available, a host of challenges and data gaps exist that pose barriers to expanding care to all those in need of treatment. The two-day consultation featured presentations and facilitated discussion on topics including:
Participants described HCV treatment access challenges and opportunities that exist at systems, organizational, governmental, and provider levels, and discussed strategies to improve national efforts to address them. Specific key issues and potential actions were discussed such as:
Participants highlighted that in order to maximize the potential benefits of these new, curative DAAs, changes in attitude, education, awareness, policy and practice will be needed. Accurate and relevant data are required to help inform decision making and understand the strategies and policies can further support the systems changes needed to best meet the needs of patients with chronic HCV and the healthcare providers and systems that serve them.
This consultation reflects ongoing efforts by HHS to engage with diverse stakeholders, continue to build partnerships and collaboration among federal and nonfederal entities, and work to prevent new infections, reduce deaths and improve the health of people living with viral hepatitis, and reduce viral hepatitis health disparities in the United States.
Brian R. Edlin, MD, Chief Medical Officer, National Center HIV, Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention
Jagpreet Chhatwal, PhD, Senior Scientist, Institute for Technology Assessment, Assistant Professor, Harvard Medical School
John Coster, PhD, RPh, Director, Division of Pharmacy, Center for Medicaid & CHIP Services, Centers for Medicare & Medicaid Services
Kevin Costello, JD, Senior Associate Director and Litigation Director, Center for Health Law Policy Innovation, Harvard Law School Stacey Trooskin, MD, PhD, Director of Viral Hepatitis Programs, Philadelphia FIGHT Community Health Centers
Benjamin Linas, MD, MPH, Assistant Professor of Medicine and Epidemiology, Boston University, Director HIV Epidemiology and Outcomes Research Unit, Section of Infectious Diseases, Boston Medical Center
Steve Miller, MD, MBS, Senior Vice President & Chief Medical Officer, Express Scripts
You should be aware of the general risks of transmitting information over the Internet, which may not use encryption. You should therefore not share any personal medical information that you would wish to be held confidential in a physician/patient or similar clinical relationship.
The information contained on this website is not intended, should not substitute for, or be used instead of, a clinical or therapeutic relationship with a health care professional who is fully familiar with the specifics of your case. The information on this site may assist you in your personal, general research but none of it constitutes the practice of medicine or any other health care profession.
Nothing in this site is intended as a recommendation or endorsement of any specific tests, products, procedures, healthcare provider, opinions, or other information that may be mentioned in this site. Any reliance on any information provided by the website personnel, others appearing on the site at the invitation of the website and/or other visitors to the site is solely at the user's risk.
E-mail correspondence with Dr. Robert G. Gish Consultants, LLC or any of its employees, or agents, does not create a physician/patient relationship between us or cause Dr. Gish to create or retain any medical records about you, monitor your care, or communicate with your own health care provider.
Always seek the advice of your physician or other qualified health care provider with any questions you have regarding your medical care. If you suspect that you may have a medical condition, or are seeking medical advice or treatment, we recommend that you consult a qualified health professional as soon as possible.